Sonic Healthcare Ltd (ASX: SHL) Share Price and News

Mr Wilks has a background in investment banking and was previously a partner in a private investment bank. Mr Wilks has held directorships in several public companies and is currently a Nonexecutive Director of Silex Systems Limited (since 1988), a listed company divested by Sonic in 1996.

Dr Goldschmidt Goldschmidt became CEO of Sonic in 1993 and has led Sonic's global expansion by committing the Company to a model of Medical Leadership, which incorporates operational and cultural attributes focused on care for staff and quality service to doctors and patients. He is a member of Sonic's Risk Management Committee and holds memberships with numerous industry, medical and laboratory associations.

Mr Compton has senior executive experience in healthcare services. He is currently Adjunct Professor in Management (Healthcare Leadership) at Macquarie University (Macquarie Business School), and Non-executive Chairman of not-for-profit organizations St Luke's Care and the Order of St John (St John Ambulance). His previous experience includes Chief Executive Officer of each of St Luke's Care, Immune Systems Therapeutics Limited and the Royal Flying Doctor Service of Australia.

Mr Mitchell has international healthcare and finance experience. He has also performed roles with a number of industry and government committees. Mr Mitchell is member of the Risk Management Committee.

Mr Panaccio has executive management experience in business and healthcare services. He is also a Non-executive Director of Unison Housing Limited, Non-executive Chairman of Azure Health Technology Limited, NeuralDx Limited and Magellan Stem Cells Pty Ltd (from August 2023). Mr Panaccio was the Chief Executive Officer and Executive Director of Melbourne Pathology (acquired by Sonic in 1999) for ten years to 2001, the Chief Executive Officer of Monash IVF until 2009, the Executive Chairman of Health Networks Australia until 2017 and a Non-executive Director of Haemokinesis Limited until October 2022. Mr Panaccio is a member of the Risk Management Committee.

Professor Crowe was a Non-executive Director of St Vincent's Health Australia Ltd from January 2013 until October 2021. She retired from Burnet Institute as Associate Director in 2018 following a 30-year research career, having played a role in Burnet's development as a global research organization. Professor Crowe retired as Principal Specialist in Infectious Diseases at The Alfred Hospital, Melbourne in 2019 after 35 years of service. She has served as a Member of the Prime Minister's Science Engineering and Innovation Council (India/China Working Group), as Head of the World Health Organization (WHO) Regional Reference Laboratory for HIV Resistance Testing and as an HIV advisor to WHO for 25 years. Professor Crowe is Chair of the Risk Management Committee.

Prof Bennett has over 40 years of healthcare industry experience across the private, public and not-for-profit sectors. Her roles have involved providing clinical care, strategic planning, and senior operational management. She has an active commitment to and involvement in medical professional issues, social policy and medical research. She is an experienced non-executive director in publicly listed, private and social enterprises. She is currently a non-executive director of ASX-listed Regis Healthcare (since March 2018), and an outgoing non-executive director of Telstra Health Pty Ltd. In December 2021, Professor Bennett retired from The University of Notre Dame Australia where she was Deputy Vice Chancellor, Enterprise & Partnerships (in 2020 and 2021) and Dean, School of Medicine, Sydney for over ten years. Her professional experience has included being Group Executive and Chief Medical Officer for MBF and the Bupa Health and Care services, CEO and later Chair of Research Australia, Managing Director of Total Health Enterprise Ltd, Partner in Health and Life Sciences for KPMG Australia, CEO of Westmead Hospital and Community Health Services, General Manager for the Royal Hospital for Women and Head of Planning in NSW Health.

Ms Spargo has gained business experience as both a legal advisor, having worked in private practice and government, and as a director. Ms Spargo also holds non-executive director roles with CIMIC Group Limited (from September 2017), the Future Fuels Cooperative Research Centre, Geelong Football Club Limited and Jellis Craig. Ms Spargo was previously a Non-executive Director of Fletcher Building Limited and Xenith IP Group Limited.

Dr Giles after initially practicing as a medical doctor, Dr Giles moved to commercial pursuits which combined science, medicine and health. Dr Giles is currently Managing Director and Chief Executive Officer of OncoRes Medical (since 2017), which specialises in biomedical innovation. Dr Giles is also a Venture Partner at Brandon Capital Partners (since 2012), a venture capital firm dedicated to developing and supporting Australian life sciences businesses. She was previously an Investment Manager with Stone Ridge Ventures, a fund manager specialising in seed-to-early-stage technology investment. Dr Giles has start-up experience in medical apps, diagnostics and fitness devices and has served on the boards of private healthcare-related technology companies. She is a member of the Curtin University Commercialisation Advisory Board.

-

-